

- stiff-person syndrome, 618  
visual syndromes, 619  
pemphigus, 361, 361t, 370t, 372  
in renal cell carcinoma, 578
- Paranoá virus, 1308t
- Paraparesis, 156–157, 156f
- Parapharyngeal space infections, 235
- Paraphasia, 177
- Paraplegin* gene, 2634t, 2636
- Parapneumonic effusion, 951, 1717
- Parapoxviruses, 220e-1t, 220e-2
- Paraproteinemia, 404. *See also* Plasma cell disorders
- Parapsoriasis, 353, 353t
- Parasite(s)  
adherence of, 145e-2t, 145e-3  
entry into host, 145e-1  
laboratory identification of, 245e-1  
alternative procedures, 245e-5t  
blood and tissue parasites, 245e-1–4  
flatworm infections, 245e-2t. *See also* Cestodes/cestode infections; Trematodes/trematode infections  
intestinal parasites, 245e-1  
minor procedures, 245e-5t  
molecular methods, 245e-6, 245e-6t  
nonspecific tests, 245e-4, 245e-6  
protozoal infections, 245e-4t. *See also* Protozoa  
roundworm infections, 245e-3t. *See also* Nematodes/nematode infections  
tissue invasion by, 145e-8
- Parasitic infections. *See also specific infections*  
arthritis in, 837–838  
as cause of fever of unknown origin, 137t  
hepatobiliary, 2084  
myocarditis in, 1560–1561  
polymyositis, 2198  
renal involvement in, 1849–1850  
transfusion-transmitted, 138e-6  
in transplant recipient, 921  
treatment of, 246e-1
- Parasomnias, 192–193
- Parathyroid disorders  
adenoma, 2470  
carcinoma, 2471, 2473  
genetic considerations in, 2471–2472, 2471f  
hyperparathyroidism. *See* Hyperparathyroidism  
Hyperparathyroidism  
hyperparathyroidism-jaw tumor syndrome. *See* Hyperparathyroidism-jaw tumor (HPT-JT) syndrome  
hyperplasia, 2470  
hypoparathyroidism. *See* Hypoparathyroidism  
in MEN syndromes. *See entries at* Multiple endocrine neoplasia
- Parathyroidectomy, 2473–2474, 2487
- Parathyroid hormone (PTH), 2466  
actions of, 313, 313f, 2466–2467  
assessment of, 400e-6  
in calcium homeostasis, 2457, 2476F  
in chronic kidney disease, 333e-3, 1815, 1816  
deficiency of, 314–315  
ectopic production of, 314, 511, 608, 609t  
excess of, 313  
exogenous injection of. *See* Teriparatide  
half-life of, 400e-2  
in hypercalcemia, 2480  
for hypoparathyroidism, 2484  
metabolism of, 2467–2468  
in primary hyperparathyroidism, 2473, 2473f  
vs. PTHrP, 2468, 2468f  
receptor cross-talk of, 400e-1  
reference values for, 2762t  
regulation of, 2467  
resistance to, 2486F, 2486f  
structure of, 2467, 2468f  
synthesis of, 2467
- Parathyroid hormone (PTH)/PTHrP receptor, 400e-1, 2469, 2469f, 2476f
- Parathyroid hormone-related protein (PTHrP), 2468  
actions of, 2468–2469, 2469f  
ectopic production of, 609–610, 609t
- vs. PTH, 400e-1, 2468, 2468f  
structure of, 2468, 2468f
- Paratonia (gegenhalten), 154
- Parcopa, for PD, 2616t
- PARD3B* gene, 1241t
- Parechoviruses, 894, 1294–1295
- Parental disomy, 597
- Parental imprinting, 101e-4
- Parenteral nutrition, 98e-1. *See also* Specialized nutritional support  
catheter placement for, 98e-3–4, 98e-6  
cholestasis in, 284, 2030  
combined with enteral feeding, 98e-3  
complications of, 98e-6–8, 98e-7t, 295  
definition of, 98e-1  
diabetes mellitus and, 2421  
electrolyte additions to, 98e-5, 98e-5t  
global considerations in, 98e-9  
home, 98e-4  
hypercalcemia in, 313  
indications for, 98e-3  
metabolic alkalosis in, 322  
mineral supplementation in, 98e-6t  
monitoring of, 98e-6, 98e-6t  
nutrient composition of, 95e-4  
risks of, 98e-3, 431e-5  
vitamin requirements in, 98e-5, 98e-5t
- Paresis, 1136. *See also* Periodic paralysis
- Paresthesia, 158, 1946t
- Parietal cell, 1911, 1912f, 1913
- Parietal cell antibodies, 645
- Parietal cortex, posterior, 180, 180f
- Parietal lesions, 209
- Parietofrontal network, 180, 180f
- Parinaud's syndrome/complex  
in *Bartonella* infections, 1079  
clinical features of, 195, 210  
etiology of, 210  
in pineal region tumors, 602  
in tularemia, 1067
- Parkes-Weber syndrome, 1651, 1654
- parkin* gene mutations, 2609, 2613
- Parkinsonism  
ALS and, 2633, 2635t  
atypical, 2609–2611, 2612t  
differential diagnosis of, 2610t  
drug-induced, 2611, 2624  
gait disorders in, 162t, 163  
lower body, 163  
in multiple system atrophy, 2641  
secondary, 2611, 2612t  
in Wilson's disease. *See* Wilson's disease
- Parkinson's disease (PD), 2609  
AD and, 2599  
clinical features of, 2609, 2609t  
autonomic disturbances, 2617–2618  
cardinal, 2609, 2609t  
constipation, 274, 2618  
delirium, 166  
dementia, 171, 2599, 2605, 2617  
dysphagia, 256, 257  
frontal lobe syndrome, 184  
motor, 33e-1v, 163, 2609, 2609t, 2618  
nonmotor, 2609t, 2617–2618  
olfactory dysfunction, 211, 214–215  
psychoses, 2617  
seborrhheic dermatitis, 347  
sleep disorders, 191, 192, 2618  
deaths from, 6e-1t  
differential diagnosis of, 2609–2611, 2610t, 2612t  
ECG in, 278e-5f  
in elderly, 82  
etiology of, 2611–2613  
falls in, 163  
familial, 444e-9, 2611–2612  
frailty and, 77, 82  
genetic considerations in, 444e-9–10, 2611–2612, 2612t  
imaging in, 2609, 2611f  
pathophysiology of, 2609, 2610f, 2611f, 2612f, 2613, 2613f  
prevalence of, 2609  
prions in, 453e-1, 2612
- vs. progressive supranuclear palsy, 2605  
treatment of, 2613  
amantadine, 2616  
anticholinergics, 2615  
approach to, 2618, 2619f  
COMT inhibitors, 2615, 2616t  
deep brain stimulation, 2616, 2618  
dopamine agonists, 2615, 2616t, 2618  
experimental, 2617  
gene delivery, 2617  
levodopa, 2613–2614, 2614f, 2616t, 2618  
MAO-B inhibitors, 2615, 2616t, 2618  
neuroprotective agents, 2616  
for nonmotor and nondopaminergic features, 2617–2618  
nonpharmacologic, 2618  
stem cell therapy, 90e-3, 444e-7, 2617  
surgical, 2616–2617
- Parkinson's disease dementia (PDD), 171, 2605–2606, 2617
- Paromomycin  
action of, 246e-11  
adverse effects of, 246e-2t, 246e-11, 942, 1391  
for amebiasis, 246e-9, 1366  
for cutaneous leishmaniasis, 1393  
for *D. fragilis* infections, 1409  
for *Giardia* infections, 1406  
indications for, 246e-2t  
pharmacology of, 246e-11  
in pregnancy and lactation, 246e-2t  
for visceral leishmaniasis, 1391
- Paronychia, 351  
*Candida*, 1343  
drug-induced, 380, 380f  
*P. aeruginosa*, 1047
- Parotid gland  
bilateral enlargement of, 2167t  
tumors, 503
- Parotitis  
acute bacterial, 241  
differential diagnosis of, 231e-3  
in mumps infection, 231e-2, 231e-2f
- Paroxetine  
adverse effects of, 2392, 2710t, 2716  
for anxiety disorders, 2711  
for depression, 64, 473, 2710t, 2716  
drug interactions of, 34t, 40  
for hot flashes, 623  
for irritable bowel syndrome, 1969  
for menopausal symptoms, 2383  
metabolism of, 34t  
for panic disorder, 2709  
pharmacology of, 2717  
for PTSD, 2712
- Peroxysmal AV block, 1473, 1473f
- Peroxysmal cold hemoglobinuria, 657t, 659
- Peroxysmal dyskinesias, 2624–2625
- Peroxysmal hemikeratoma, 107, 109t, 2595t, 2596
- Peroxysmal junctional reciprocating tachycardia, 1481
- Peroxysmal kinesigenic dyskinesia (PKD), 2624–2625
- Peroxysmal nocturnal dyspnea, 1503–1504
- Peroxysmal nocturnal hemoglobinuria, 660  
clinical features of, 282, 399, 660, 660f, 664  
diagnosis of, 660, 660f  
natural history of, 660  
pathophysiology of, 660, 661f  
treatment of, 661–662, 661f
- Peroxysmal nonkinesigenic dyskinesia (PNKD), 2625
- Peroxysmal supraventricular tachycardia (PSVT). *See also* Supraventricular tachyarrhythmias  
accessory pathways and, 1481  
AV nodal reentry tachycardia, 278e-7f, 1478f, 1479–1480, 1481f  
AV reentry tachycardia, 1478f, 1481  
mechanisms of, 1478f  
orthodromic AV reentry tachycardia, 1481  
preexcited tachycardias, 1482, 1483f  
treatment of, 1483–1484, 1483f  
vs. ventricular tachycardia, 1494  
PARP inhibition, 102e-6f, 102e-7, 529